fluorouracil has been researched along with Splenic Diseases in 2 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
Splenic Diseases: Diseases involving the SPLEEN.
| Excerpt | Relevance | Reference |
|---|---|---|
| " However, it was repeatedly shown that the sequence of 5-FU followed by CDDP is more active and less toxic in tumor-bearing animals." | 1.33 | Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice. ( Fujimoto, S, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ohta, R | 1 |
| Yamada, T | 1 |
| Hara, K | 1 |
| Iwai, T | 1 |
| Tanakaya, K | 1 |
| Ishibashi, K | 1 |
| Yoshimatsu, K | 1 |
| Kosugi, C | 1 |
| Tsubaki, M | 1 |
| Nakajima, H | 1 |
| Oya, M | 1 |
| Yoshida, H | 1 |
| Koda, K | 1 |
| Ishida, H | 1 |
| Fujimoto, S | 1 |
1 trial available for fluorouracil and Splenic Diseases
| Article | Year |
|---|---|
Oxaliplatin-induced increase in splenic volume: experiences from multicenter study in Japan.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Colonic Neoplasms; Dis | 2020 |
1 other study available for fluorouracil and Splenic Diseases
| Article | Year |
|---|---|
Schedule-dependent antitumor activity and toxicity of combinations of 5-fluorouracil and cisplatin/carboplatin against L1210 leukemia-bearing mice.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Ascites; Carboplatin | 2006 |